PMID- 38027178
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20240228
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Metabolite profiles of diabetes mellitus and response to intervention in 
      anti-hyperglycemic drugs.
PG  - 1237934
LID - 10.3389/fendo.2023.1237934 [doi]
LID - 1237934
AB  - Type 2 diabetes mellitus (T2DM) has become a major health problem, threatening 
      the quality of life of nearly 500 million patients worldwide. As a typical 
      multifactorial metabolic disease, T2DM involves the changes and interactions of 
      various metabolic pathways such as carbohydrates, amino acid, and lipids. It has 
      been suggested that metabolites are not only the endpoints of upstream 
      biochemical processes, but also play a critical role as regulators of disease 
      progression. For example, excess free fatty acids can lead to reduced glucose 
      utilization in skeletal muscle and induce insulin resistance; metabolism disorder 
      of branched-chain amino acids contributes to the accumulation of toxic metabolic 
      intermediates, and promotes the dysfunction of beta-cell mitochondria, stress signal 
      transduction, and apoptosis. In this paper, we discuss the role of metabolites in 
      the pathogenesis of T2DM and their potential as biomarkers. Finally, we list the 
      effects of anti-hyperglycemic drugs on serum/plasma metabolic profiles.
CI  - Copyright (c) 2023 Liu, Wang and Liu.
FAU - Liu, Yanzhong
AU  - Liu Y
AD  - Provincial University Key Laboratory of Sport and Health Science, School of 
      Physical Education and Sport Sciences, Fujian Normal University, Fuzhou, China.
FAU - Wang, Dan
AU  - Wang D
AD  - Provincial University Key Laboratory of Sport and Health Science, School of 
      Physical Education and Sport Sciences, Fujian Normal University, Fuzhou, China.
FAU - Liu, Yi-Ping
AU  - Liu YP
AD  - Provincial University Key Laboratory of Sport and Health Science, School of 
      Physical Education and Sport Sciences, Fujian Normal University, Fuzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231031
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Amino Acids, Branched-Chain)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Quality of Life
MH  - *Insulin Resistance/physiology
MH  - Amino Acids, Branched-Chain/metabolism
MH  - Hypoglycemic Agents/therapeutic use
PMC - PMC10644798
OTO - NOTNLM
OT  - amino acids
OT  - carbohydrates
OT  - diabetes mellitus
OT  - lipids
OT  - metabolites
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/29 18:43
MHDA- 2023/12/01 06:44
PMCR- 2023/01/01
CRDT- 2023/11/29 17:02
PHST- 2023/06/10 00:00 [received]
PHST- 2023/10/16 00:00 [accepted]
PHST- 2023/12/01 06:44 [medline]
PHST- 2023/11/29 18:43 [pubmed]
PHST- 2023/11/29 17:02 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1237934 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Oct 31;14:1237934. doi: 
      10.3389/fendo.2023.1237934. eCollection 2023.